Help
842 Article Views
Publication Date: 31 Oct 2011
Journal: Clinical Medicine Insights: Oncology
doi: 10.4137/CMO.S7263
This review is informative on the hot topic of TKI therapies for renal cell carcinoma.
Advances in our understanding of renal cancer biology have led to a new treatment paradigm in renal cancer. Tyrosine kinase inhibitors (TKI), that target the intracellular kinase domain of the VEGF receptor, have become established as the most successful class of agent in this disease. Three TKIs are currently approved for use in patients with advanced disease. Newer, more potent inhibitors have reached phase III clinical testing, meaning others are likely to follow. In 2009, pazopanib became the most recent TKI to receive FDA approval. This review sets out to discuss the key opportunities and challenges associated with TKI use in RCC, focusing particularly on pazopanib. We also review the current place of pazopanib in the management of patients with advanced disease, in what is a rapidly evolving therapeutic landscape.
The reviewing and editorial management of our paper was timely, thorough, and systematic. In particular the reviewers' comments resulted in a paper significantly more robust than the first version.Dr Clark D Jeffries (University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) What Your Colleagues Say
Copyright © 2012 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)
FacebookGoogle+Twitter
PinterestTumblrYouTube